J. Mao

Association between baseline Controlling Nutritional Status Score and clinical outcomes of patients with multiple myeloma.

Jun Xia, Hongfeng Guo, Jing Wang, 2021, Cancer biomarkers : section A of Disease markers.

Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study

Jiannan Ye, Xin Zhou, J. Mao, 2020, Oncology Research and Treatment.

Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience

Jun Xia, Xifeng Qian, Hongfeng Guo, 2016, Hematology.

Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy.

Hongfeng Guo, Xin Xie, J. Mao, 2015, International journal of clinical and experimental medicine.

Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.

Hongfeng Guo, Jing Wang, Xin Zhou, 2010, Clinical lymphoma, myeloma & leukemia.

Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma.

Ke Wang, Hongfeng Guo, Yun-feng Shen, 2012, World journal of gastroenterology.

Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma.

Jun Xia, Hongfeng Guo, Jing Wang, 2018, Cancer biomarkers : section A of Disease markers.

Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series

Hongfeng Guo, Jing Wang, Xin Zhou, 2014, Experimental and therapeutic medicine.

Bortezomib plus intermediate‐dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience

Feng Chen, Guohua Yang, Yun Zhuang, 2010, American journal of hematology.